Switch Maintenance Therapy for Metastatic Urothelial Carcinoma.

Bladder Cancer · 2022 · PMC11181790 · PMID 38994180

Europe PMC DOI

hedged sentence

0.1820

closest p · 3.6× alpha

0.1820

boldest claim

The sentences

showed a trendp = 0.182not close (p > 0.1)

Vinflunine showed a trend towards improved OS; median OS in vinflunine vs BSC group was 16.7 months vs 13.2 months respectively (HR-0.736; 95% CI, 0.44–1.24, p = 0.182); objective responses were achieved in 21% patients in vinflunine group vs 7% in BSC group respectively and vinflunine had an acceptable safety profile.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.